AbbVie: SKYRIZI shows positive Phase 3 results for Crohn's disease
FROM THE WIRE · FINANCE.YAHOO.COM
Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboi Results build on previously reported week 12 findings in which SKYRIZI achieved superiority in the co-primary endpoints of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 3 data support FDA approval application for subcutaneous formulation, potential growth driver for the drug.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01SKYRIZI achieved superior clinical remission and endoscopic response versus placebo.
- 02Higher rates of endoscopic remission and ulcer-free endoscopy observed with treatment.
- 03Data support FDA application for new subcutaneous induction dosing regimen.
- 04Results presented at American College of Gastroenterology 2026 Annual Meeting.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets